12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-TTRRx: Phase II/III started

Isis began a double-blind, placebo-controlled, international Phase II/III trial to evaluate 300 mg subcutaneous ISIS-TTRRx given 3 times in the first week followed by once-weekly for 64 weeks in...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >